The U.S. district attorney for Massachusetts filed suit against the drugmaker this week, alleging that it paid tens of millions in kickbacks through a copay foundation for Eylea, a drug used to treat macular degeneration.
The U.S. Department of Justice was investigating Practice Fusion over allegations it violated HIPAA and anti-kickback laws and wrongfully obtained certification for its software from the HHS.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The deal struck Thursday follows similar settlements between the Department of Justice and three other drugmakers. The department alleged that the companies started copay-assistance funds that violated anti-kickback laws.
According to the DOJ, this is the ninth consecutive year that the organizations' civil healthcare fraud settlements and judgments have exceeded $2 billion.
In an investigation published Sunday, The Austin (Texas) American-Statesman could find no specific case of someone being charged with fraud related to neuromonitoring, but payers and regulators are concerned.
I think it was Prozac that taught me how to ski. Thanks to Zoloft (and having psychiatrists for parents), I became a Penguins fan and Zyprexa kept me flush with pens, scratch paper and lunch bags. It was the 90s, and pharmaceutical swag – and swagger – was at its pinnacle. Things have changed remarkably since those pre-kickback […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.